Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.27), $0.11 worse than the analyst estimate of ($0.16).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.